Clinical Trial

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with overweight or obesity. It is a multiple ascending dose study in participants with overweight or obesity during the 4-week treatment period.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-07.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-12-29
Trial Details
NCT Number NCT07170319
Lead Sponsor Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions Overweight or Obesity
Enrollment 79 participants
Start Date 2025-09-25
Primary Completion 2025-12-24 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-31